An interventional study of Treat Regimen in Nonsmall Cell Lung Cancer, sponsored by Wen-zhao ZHONG. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Wen-zhao ZHONG · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to evaluate the effectiveness and safety of a locally deployed artificial intelligence (AI) decision-support model in the multidisciplinary team (MDT) process for patients with non-small cell lung cancer (NSCLC).
The main questions it aims to answer :
What is the level of agreement between treatment recommendations generated by the AI model and those made by a traditional MDT? How often do clinicians modify their final treatment decision after reviewing the AI model's recommendation? Researchers will compare treatment plans from the traditional MDT (Arm 1), the AI model (Arm 2), and the clinician's final decision after reviewing the AI output (Arm 3) to assess consistency, decision modification rates, and clinical efficiency.
Participants will:
Have their clinical, imaging, and molecular data submitted to both the traditional MDT and the AI model for independent treatment recommendations Receive a final treatment plan determined by clinicians after reviewing both recommendations, with follow-up for safety and survival outcomes
6,488 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,632 are open to participants now.
This study's planned enrollment of 300 is above the median of 62 across 5,213 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Wen-zhao ZHONG is the lead sponsor of 9 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Diagnostic Test: Treat Regimen
The impact of artificial intelligence on clinicians' treatment plans
Consistency rate
Consistency rate between Option 1 and Option 2 (calculated using Kappa value). Consistency rate between Option 1 and Option 3 (decision modification rate).
Time frame: Baseline(MDT 1 Day)
MDT Discussion Process Time
Time from start to end of multidisciplinary team (MDT) discussion, measured immediately after MDT end.
Time frame: Baseline(MDT Day 1)
Quality of AI Recommendations
Physician-rated quality of AI recommendations using a Likert 5-point scale (1 = very poor, 5 = excellent).
Time frame: Baseline(MDT Day 1)
Clinical Acceptability of AI
Physician-rated clinical acceptability of AI recommendations using a Likert 5-point scale (1 = unacceptable, 5 = fully acceptable).
Time frame: Baseline(MDT Day 1)
MDT Discussion Efficiency
Physician-rated efficiency of MDT discussion process aided by AI using a Likert 5-point scale (1 = very inefficient, 5 = very efficient).
Time frame: Baseline(MDT Day 1)
Process Convenience
Physician-rated convenience of the AI-integrated workflow using a Likert 5-point scale (1 = very inconvenient, 5 = very convenient).
Time frame: Baseline(MDT Day 1)
Added Value to Clinical Decision
Physician-rated added value of AI to clinical decision-making using a Likert 5-point scale (1 = no added value, 5 = significant added value).
Time frame: Baseline(MDT Day 1)
Learning and Training Value
Physician-rated learning and training value of AI system using a Likert 5-point scale (1 = no value, 5 = high value).
Time frame: Baseline(MDT Day 1)
Overall Satisfaction
Physician-rated overall satisfaction with AI-assisted MDT using a Likert 5-point scale (1 = very dissatisfied, 5 = very satisfied).
Time frame: Baseline(MDT Day 1)
Willingness to Use in Future
Physician-rated willingness to use AI system in future clinical practice using a Likert 5-point scale (1 = definitely not willing, 5 = definitely willing).
Time frame: Baseline(MDT Day 1)
Disease-Free Survival (DFS)
Time from treatment initiation to disease recurrence or death from any cause, assessed every 3-6 months during 2-3 years follow-up.
Time frame: 3 years
Progression-Free Survival (PFS)
Time from treatment initiation to disease progression or death from any cause, assessed every 3-6 months during 2-3 years follow-up.
Time frame: 3 years
Overall Survival (OS)
Time from treatment initiation to death from any cause, assessed every 3-6 months during 2-3 years follow-up.
Time frame: 3 years
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided — Patient information cannot be disclosed.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung→
Wen-zhao ZHONG